Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

Core Insights - Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with immune and inflammatory diseases [1][2] - The company's lead asset is pacibekitug, also known as TOUR006 [2] Upcoming Events - Sandeep Kulkarni, MD, Co-Founder and CEO of Tourmaline, will participate in the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, at 1:30 pm ET [1] - A live webcast of the event will be available on the Tourmaline Bio website [1]